US EditionPublished • loading... • Updated
CorMedix’s (CRMD) Buy Rating Reaffirmed at D. Boral Capital
Summary by watchlistnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CorMedix’s (CRMD) Buy Rating Reaffirmed at D. Boral Capital
CorMedix (NASDAQ:CRMD – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. D. Boral Capital’s target price points to a potential upside of 91.39% from the stock’s previous close. Several other […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
